The U.S. District Court for the District of Columbia ruled in favor of the FDA: “Vanda is currently reviewing the U.S. District Court’s decision.
| WASHINGTON, Jan. 31, 2020 /PRNewswire/ -- Vanda Pharmaceuticals, Inc. (Vanda) (Nasdaq: VNDA) makes the following statement regarding U.S. District Court case 19-cv-30; U.S. Food and Drug Administration (FDA) v. Vanda, in which the U.S. District Court for the District of Columbia ruled in favor of the FDA: “Vanda is currently reviewing the U.S. District Court’s decision. Following a comprehensive review, we will determine the appropriate next steps.” About Vanda Pharmaceuticals Inc. Vanda is a leading global biopharmaceutical company focused on the development and commercialization of innovative therapies to address high unmet medical needs and improve the lives of patients. For more on Vanda Pharmaceuticals Inc., please visit www.vandapharma.com Corporate Contact: Elizabeth Van Every
SOURCE Vanda Pharmaceuticals Inc. | ||
Company Codes: NASDAQ-NMS:VNDA |
View original content:
